89240
document
Marginal zone B cell lymphoma of the parotid glands : results of a randomised trial comparing radiotherapy to combined therapy . 39 patients with marginal zone B cell lymphoma ( MZBCL ) of the parotid glands ( stages I or II ) were studied . They were randomized to be treated with either radiotherapy alone ( extended fields , 4500 cGy ) or radiotherapy ( the same schedule ) plus adjuvant chemotherapy ( cyclophosphamide , vincristine and prednisone ) . The end points were survival and time to treatment failure ( TTF ) . Patients who received radiotherapy alone had a complete remission rate of 100 % , the TTF was 90 % at 5 years and overall survival at 5 years was 90 % with no statistical difference when compared with patients who received combined therapy [ 100 , 80 and 95 % , respectively ( P = 0.5 ) ] . Although adjuvant chemotherapy was well tolerated , the use of this therapeutic approach in patients with early stage MZBCL did not offer any advantage over radiotherapy alone as the initial treatment . Until now , radiotherapy was considered the treatment of choice in this clinical setting of patients .
89241
Intervention_Physical
radiotherapy
89242
Intervention_Control
combined therapy
89243
Intervention_Physical
radiotherapy alone
89244
Intervention_Physical
radiotherapy
89245
Intervention_Control
plus
89246
Intervention_Pharmacological
adjuvant chemotherapy ( cyclophosphamide , vincristine and prednisone )
89247
Intervention_Physical
radiotherapy
89248
Intervention_Physical
combined therapy
89249
Intervention_Physical
adjuvant chemotherapy
89250
Intervention_Physical
radiotherapy
89251
Outcome_Other
end points
89252
Outcome_Mortality
survival and time to treatment failure ( TTF ) .
89253
Outcome_Physical
complete remission rate
89254
Outcome_Other
TTF
89255
Outcome_Mortality
overall survival
89256
Outcome_Other
tolerated
89257
Participant_Sample-size
39
89258
Participant_Condition
marginal zone B cell lymphoma ( MZBCL )